Multiple sclerosis and related disordersHumansMultiple SclerosisRelapsing-RemittingCladribineImmunosuppressive Agents
Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region.
Ho Jin Kim, Suzanne J Hodgkinson, Long-Sun Ro, Rocksy Fransisca V Situmeang, Sasitorn Siritho, Kevin Tan, Hoang Tien Trong Nghia, Shanthi Viswanathan, Lau Yuk Lun Alexander, Hannah Loke, Ru Jin Tay, Karim Taha, Maya Zeineddine, Bassem Yamout
Published: 202610.1016/j.msard.2025.106897
Abstract
BACKGROUND: Cladribine Tablets (CladT) have emerged as a potent disease-modifying therapy (DMT) for relapsing multiple sclerosis (Pittock et al., 2019. While their efficacy and safety profiles have been well-documented in Western populations, there i…
Preview only. Read the full abstract at the source